English | Español

Abbott Laboratories
Patient Daily Report | May 22, 2023

Dr. Lakkireddy: 'Assert-IQ ICM is a significant advancement amongst the tools that are currently available for diagnoses of irregular heart rhythms'
Press release submission | Oct 26, 2018

ABBOTT: Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results

Press release submission | Oct 18, 2018

ABBOTT: New Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care
Marian Johns | Nov 17, 2017

Abbott receives approval in Japan for device to treat mitral regurgitation heart disease
Carol Ostrow | Nov 3, 2017

XIENCE implants show benefits in cardiac recovery
Mark Iandolo | Oct 26, 2017

Abbott rolls out new DRG Neurostimulator System to help combat chronic pain
Kathy Adams | Oct 6, 2017

Abbott completes acquisition of Alere
Carol Ostrow | Oct 3, 2017

Freestyle Libre gains FDA approval, ending need to prick finger for glucose testing, Abbott says

Trending
+ Pharmaceuticals
Patient Daily | Jun 23, 2025

PhRMA says patients in the U.S. face higher prescription costs due to 340B program
+ Pharmaceuticals
Patient Daily | Jun 19, 2025

Patients Come First spokesperson on 340B reform: ‘Americans deserve a system that prioritizes patients first, not pharmacy middlemen’
+ Pharmaceuticals
Patient Daily | Jun 19, 2025

FDA loophole lets low-quality drugs from China and India flood U.S. market, while American manufacturers are held to higher standards
+ Pharmaceuticals
Patient Daily | Jun 25, 2025

Neurosurgeon at the University of California: ‘340B is being exploited for profit, not patient care’